Pembrolizumab
2016-1
Phase 2 small_molecule completed
Quick answer
Pembrolizumab for Metastatic Uveal Melanoma is a Phase 2 program (small_molecule) at Syndax Pharmaceuticals Inc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Syndax Pharmaceuticals Inc
- Indication
- Metastatic Uveal Melanoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed